Understanding CAR T-cell therapy (November 2020)
Presented by Dr Michael Dickinson, Peter MacCallum Cancer Centre & Royal Melbourne Hospital
Hosted by Donna Gairns, National Nurse Manager, Lymphoma Australia
Lymphoma Australia was pleased to invite Dr Michael Dickinson, Consultant Haematologist at Peter MacCallum Cancer Centre & Royal Melbourne Hospital and disease group lead for aggressive lymphoma, as our guest speaker.
Dr Dickinson has a special interest in lymphoma and is leading the development of new targeted, non-chemotherapy drugs as the principal investigator of many trials of new treatments. He is the local investigator on a range of CAR T-cell therapy trials. Dr Dickinson has been instrumental in helping in the recent approval of publicly funded CAR T-cell therapy to Australian patients.
CAR T-cell therapy is a relatively new therapy that has gained a lot of attention in the treatment of lymphoma/CLL in recent years. Dr Dickinson provides a thorough presentation that is relevant to Australian lymphoma/CLL patients in November 2020 in an exciting area that is changing rapidly.
The presentation includes:
- What is CAR T-cell therapy?
- How does CAR T-cell therapy work?
- What is the process?
- Side effects of CAR T-cell therapy
- What subtypes are currently being treated in Australia & worldwide
- CAR T-cell therapy funding in Australia
- Clinical trials available in Australia and around the world